Base&Byte Biotechnology Co., Ltd. is an innovative startup focused on revolutionizing drug discovery, development, and validation. Leveraging groundbreaking technologies like Artificial Intelligence (AI) and Omics Big Data, our mission is to expedite the creation of new pharmaceuticals.

We are driven by the rapid advancements in technology, particularly in fields such as deep learning algorithms (including transformer and diffusion models), automation, microfluidics, and CRISPR. Our expertise lies in In Silico Design, which encompasses antibodies, proteins, peptides, AAVs, vaccines, and more. This approach not only enhances the efficiency of developing new drugs but also enables the virtual design of elusive drug targets, paving the way for pioneering 'first-in-class' drugs.

Our team comprises seasoned professionals with deep expertise in artificial intelligence, high-throughput biotechnology, and drug discovery. Together, we've forged a new-generation AI-enabled drug design platform. Our focus spans the early phases of drug development, from target identification to drug discovery, proof of concept (POC) validation, and pre-clinical candidate selection.

One of our notable achievements is the development of the NeoDesign algorithm platform, tailored for tumor neoantigen design. This platform has been implemented in investigator-initiated trials across three top-tier hospitals in China. Additionally, our ultra-efficient antibody discovery platform is in collaboration with leading pharmaceutical companies, targeting cancer and other diseases.